NCT06125197View on ClinicalTrials.gov

Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

July 23, 2024

Primary Completion Date

January 30, 2026

Study Completion Date

May 30, 2026

Conditions
Lung Cancer
Interventions
BIOLOGICAL

TILT-123

Tumor necrosis factor alpha (TNFalpha) and Interleukin-2 (IL-2) coding oncolytic adenovirus TILT-123

BIOLOGICAL

KEYTRUDA®

pembrolizumab, a monoclonal antibody binding PD-1

Trial Locations (2)

90404

NOT_YET_RECRUITING

UCLA Jonsson Comprehensive Cancer Center, Santa Monica

92658

RECRUITING

Hoag Memorial Hospital Presbyterian, Newport Beach

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

TILT Biotherapeutics Ltd.

INDUSTRY